PODD

Insulet Corporation · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website insulet.com
Employees(FY) 2600
ISIN US45784P1012

Performance

-1.9%

+1.75%

+12.15%

+35.73%

+22.85%

YTD

+28.18%

Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Advanced Technical Analysis

Technical Analysis of PODD 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Oscillators Score of 60 suggests a neutral stance that could support continued strength. Overall, the Technical Score of 78 reinforces a positive outlook, suggesting that the stock is likely to maintain its upward traject...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PODD

Stock Rank

Recent News & Updates

2024-12-19 11:57
Insulet Corporation (NASDAQ:PODD) Delivered A Better ROE Than Its Industry(Simply Wall St.)
2024-12-18 10:56
Baird Adjusts Insulet Price Target to $325 From $280, Maintains Outperform Rating(MT Newswires)
2024-12-18 10:48
Redburn Atlantic Raises Price Target on Insulet to $300 From $270, Keeps Buy Rating(MT Newswires)
2024-12-17 19:00
PODD: Lowering target price to $277.00(Argus Research)
2024-12-13 09:50
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term(Zacks)
2024-12-12 11:40
RMD or PODD: Which Is the Better Value Stock Right Now?(Zacks)
2024-12-12 11:31
Nephron Research Adjusts Price Target on Insulet to $310 From $285(MT Newswires)
2024-12-12 10:15
JPMorgan Raises Insulet Price Target to $330 From $280, Maintains Overweight Rating(MT Newswires)
2024-12-11 14:59
Inari Medical Stock Gets RS Rating Upgrade(Investor's Business Daily)
2024-12-11 11:46
Wells Fargo Adjusts Price Target on Insulet to $305 From $290, Keeps Overweight Rating(MT Newswires)
2024-12-11 11:46
Citigroup Raises Price Target on Insulet to $310 From $283, Keeps Buy Rating(MT Newswires)
2024-12-10 19:00
PODD: Raising target price to $289.00(Argus Research)
2024-12-10 07:19
Jefferies Adjusts Price Target on Insulet to $340 From $300, Maintains Buy Rating(MT Newswires)
2024-12-09 09:11
Canaccord Genuity Adjusts Price Target on Insulet to $304 From $269, Keeps Buy Rating(MT Newswires)
2024-12-09 07:22
Should You Continue to Retain Insulet Stock in Your Portfolio Now?(Zacks)
2024-12-05 07:19
Insulet awarded $452M in EOFlow patent fight(MedTech Dive)
2024-12-04 16:28
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court(Business Wire)
2024-12-04 03:28
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court(Businesswire)
2024-12-03 19:00
PODD: Raising target price to $283.00(Argus Research)
2024-12-03 14:51
Novocure Stock Earns 96 RS Rating(Investor's Business Daily)
2024-11-29 09:45
Here's Why Insulet (PODD) is a Strong Growth Stock(Zacks)
2024-11-26 19:00
PODD: Raising target price to $280.00(Argus Research)
2024-11-26 08:30
If You Invested $1000 in Insulet a Decade Ago, This is How Much It'd Be Worth Now(Zacks)
2024-11-22 10:15
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US(Zacks)
2024-11-21 08:27
Insulet adds Abbott’s FreeStyle Libre 2 Plus to Omnipod 5’s compatibility roster(Medical Device Network)
2024-11-20 19:30
Insulet Announces Omnipod 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.(Businesswire)
2024-11-20 08:30
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.(Business Wire)
2024-11-20 05:11
Baptista Downgrades Insulet to Underperform(MT Newswires)
2024-11-16 07:27
Insulet's (NASDAQ:PODD) Solid Profits Have Weak Fundamentals(Simply Wall St.)
2024-11-15 06:00
Insulet to Present at Upcoming Investor Conferences(Business Wire)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.